Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Free access | 10.1172/JCI109089

Methscopolamine Inhibition of Sleep-Related Growth Hormone Secretion: EVIDENCE FOR A CHOLINERGIC SECRETORY MECHANISM

Wallace B. Mendelson, Natarajan Sitaram, Richard Jed Wyatt, and J. Christian Gillin

Laboratory of Clinical Psychopharmacology, National Institute of Mental Health, Bethesda, Maryland 20014

Division of Special Mental Health Research, Intramural Research Program, National Institute of Mental Health, Bethesda, Maryland 20014

Unit on Sleep Studies, Biological Psychiatry Branch, Division of Clinical and Biological Research, Intramural Research Program, National Institute of Mental Health, Bethesda, Maryland 20014

Metabolism Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110

Find articles by Mendelson, W. in: PubMed | Google Scholar

Laboratory of Clinical Psychopharmacology, National Institute of Mental Health, Bethesda, Maryland 20014

Division of Special Mental Health Research, Intramural Research Program, National Institute of Mental Health, Bethesda, Maryland 20014

Unit on Sleep Studies, Biological Psychiatry Branch, Division of Clinical and Biological Research, Intramural Research Program, National Institute of Mental Health, Bethesda, Maryland 20014

Metabolism Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110

Find articles by Sitaram, N. in: PubMed | Google Scholar

Laboratory of Clinical Psychopharmacology, National Institute of Mental Health, Bethesda, Maryland 20014

Division of Special Mental Health Research, Intramural Research Program, National Institute of Mental Health, Bethesda, Maryland 20014

Unit on Sleep Studies, Biological Psychiatry Branch, Division of Clinical and Biological Research, Intramural Research Program, National Institute of Mental Health, Bethesda, Maryland 20014

Metabolism Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110

Find articles by Wyatt, R. in: PubMed | Google Scholar

Laboratory of Clinical Psychopharmacology, National Institute of Mental Health, Bethesda, Maryland 20014

Division of Special Mental Health Research, Intramural Research Program, National Institute of Mental Health, Bethesda, Maryland 20014

Unit on Sleep Studies, Biological Psychiatry Branch, Division of Clinical and Biological Research, Intramural Research Program, National Institute of Mental Health, Bethesda, Maryland 20014

Metabolism Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110

Find articles by Gillin, J. in: PubMed | Google Scholar

Published June 1, 1978 - More info

Published in Volume 61, Issue 6 on June 1, 1978
J Clin Invest. 1978;61(6):1683–1690. https://doi.org/10.1172/JCI109089.
© 1978 The American Society for Clinical Investigation
Published June 1, 1978 - Version history
View PDF
Abstract

We have examined the effects of cholinergic blockade with 0.5 mg methscopolamine bromide, intramuscularly, on sleep-related and insulin-induced growth hormone (GH) secretion. 17 normal young men were studied; 8 had sleep studies, and 12 (including 3 who also had sleep studies) had insulin tolerance tests (ITT) with 0.1 U/kg of regular insulin. After an adjustment night in the sleep laboratory, saline control night and methscopolamine night studies were done in random sequence; study procedures included electroencephalographic, electromyographic, and electrooculographic recordings, and blood sampling every 20 min for hormone radioimmunoassays. Prolactin levels were also measured during sleep. For methscopolamine night studies, the mean overall control GH level of 2.89±0.44 ng/ml and the mean peak control GH level of 11.09±3.11 ng/ml were dramatically reduced to 0.75±0.01 and 1.04±0.25 ng/ml, respectively (P<0.0001 and <0.001). Despite virtual absence of GH secretion during the night in every study subject, no measured sleep characteristic was affected by methscopolamine, including total slow-wave sleep (12.1±2.6% control vs. 10.3±2.5% drug, P>0.2). Sleep prolactin levels were not changed by methscopolamine. In contrast to the abolition of sleep-related GH secretion, administration of methscopolamine had only a marginal effect on the GH response to insulin hypoglycemia. None of nine time points differed significantly, as was also the case with peak levels, mean increments, and areas under the curves (P>0.2). Analysis of variance did, however, indicate that the lower GH concentrations achieved during ITT after methscopolamine (average 31.7% below control) were significantly different than control concentrations. We conclude that the burst of GH secretion which normally occurs after sleep onset is primed by a cholinergic mechanism which does not influence slow-wave sleep. Cholinergic mechanisms do not appear to play an important role in sleep-related prolactin secretion. The contrast between the complete suppression of sleep-related GH release and the relatively small inhibitory effect on ITT-induced GH secretion suggests that the neurotransmitter mechanisms, and presumably the pathways, which subserve sleep-related GH secretion in man may be different from those which mediate the GH response to pharmacologic stimuli such as insulin.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1683
page 1683
icon of scanned page 1684
page 1684
icon of scanned page 1685
page 1685
icon of scanned page 1686
page 1686
icon of scanned page 1687
page 1687
icon of scanned page 1688
page 1688
icon of scanned page 1689
page 1689
icon of scanned page 1690
page 1690
Version history
  • Version 1 (June 1, 1978): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts